Dermata Therapeutics (NASDAQ:DRMA) Announces Earnings Results

by · The Cerbat Gem

Dermata Therapeutics (NASDAQ:DRMA – Get Free Report) released its earnings results on Wednesday. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.05, FiscalAI reports.

Dermata Therapeutics Trading Down 4.0%

DRMA stock traded down $0.05 during trading on Wednesday, hitting $1.19. The company had a trading volume of 62,601 shares, compared to its average volume of 1,426,614. The business has a 50-day moving average of $1.28 and a 200-day moving average of $2.01. Dermata Therapeutics has a one year low of $1.10 and a one year high of $8.50. The stock has a market cap of $4.79 million, a PE ratio of -0.13 and a beta of 0.67.

Analysts Set New Price Targets

A number of research analysts have issued reports on DRMA shares. Wall Street Zen upgraded Dermata Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Weiss Ratings cut Dermata Therapeutics from a “sell (e+)” rating to a “sell (e)” rating in a research report on Monday, May 4th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $10.00.

Read Our Latest Stock Report on Dermata Therapeutics

Institutional Trading of Dermata Therapeutics

An institutional investor recently bought a new position in Dermata Therapeutics stock. Clear Street Group Inc. bought a new stake in Dermata Therapeutics, Inc. (NASDAQ:DRMA – Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 17,000 shares of the company’s stock, valued at approximately $39,000. Clear Street Group Inc. owned about 0.60% of Dermata Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 8.67% of the company’s stock.

Dermata Therapeutics Company Profile

(Get Free Report)

Dermata Therapeutics is a clinical-stage immunodermatology company dedicated to developing novel small-molecule therapies for inflammatory skin disorders. The company’s lead clinical candidate, DMVT-502, is being evaluated in atopic dermatitis, while DMVT-505 is in development for vitiligo. In addition to these programs, Dermata advances preclinical assets targeting other indications such as alopecia areata.

At the core of Dermata’s approach is a proprietary drug discovery platform that combines structure-based design, medicinal chemistry and innovative formulation techniques.

See Also